asterric acid: structure given in first source; inhibits the binding of endothelin-1 to the ET(A) receptor of A10 cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3080568 |
| CHEMBL ID | 469424 |
| SCHEMBL ID | 6046569 |
| MeSH ID | M0211469 |
| Synonym |
|---|
| 577-64-0 |
| unii-j3q23xl4kn |
| j3q23xl4kn , |
| benzoic acid, 2-(2-carboxy-3-hydroxy-5-methylphenoxy)-5-hydroxy-3-methoxy-, 1-methyl ester |
| NCGC00180411-01 |
| MEGXM0_000244 |
| ACON1_001529 |
| asterric acid |
| smr000440714 |
| MLS000863583 , |
| ACON0_000930 |
| 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonyl-phenoxy)-4-meta??hyl-benzoic acid |
| xokvhfntyhpehn-uhfffaoysa- |
| inchi=1/c17h16o8/c1-8-4-11(19)14(16(20)21)12(5-8)25-15-10(17(22)24-3)6-9(18)7-13(15)23-2/h4-7,18-19h,1-3h3,(h,20,21) |
| BRD-K20637966-001-01-0 |
| L007432 |
| CHEMBL469424 , |
| 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid |
| HMS2270H17 |
| SCHEMBL6046569 |
| bdbm50711 |
| cid_3080568 |
| 2-(2-carbomethoxy-4-hydroxy-6-methoxy-phenoxy)-6-hydroxy-4-methyl-benzoic acid |
| 2-(2-methoxy-6-methoxycarbonyl-4-oxidanyl-phenoxy)-4-methyl-6-oxidanyl-benzoic acid |
| DTXSID60206405 |
| asterric acid, >=95% (lc/ms-elsd) |
| methyl 2-(2-carboxy-3-hydroxy-5-methylphenoxy)-5-hydroxy-3-methoxybenzoate |
| Q15410258 |
| tan-1415a |
| 2-hydroxy-6-(4-hydroxy-2-methoxy-6-(methoxycarbonyl)phenoxy)-4-methylbenzoic acid |
| AKOS040744937 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.6310 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 19.9526 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 13.6995 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 8.9125 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 19.9526 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 56.2341 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.0953 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.7828 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 7.0795 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 5.6234 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 8.9125 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| 67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 8.9125 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| IDH1 | Homo sapiens (human) | Potency | 23.1093 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 2.2387 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.2818 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| runt-related transcription factor 1 isoform AML1b | Homo sapiens (human) | Potency | 11.2202 | 0.0200 | 7.9858 | 39.8107 | AID504375 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.1636 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| core-binding factor subunit beta isoform 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0200 | 7.9858 | 39.8107 | AID504375 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 3.9811 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 3.1623 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 62.9025 | 0.1337 | 25.4129 | 89.1251 | AID588795; AID720498 |
| snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 7.7718 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 12.9804 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 0.8913 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 0.8913 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 0.8913 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 7.0795 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 28.1838 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 4.0554 | 0.0757 | 8.4742 | 29.0628 | AID602233; AID686980 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| SUMO-1 | Homo sapiens (human) | IC50 (µMol) | 47.1067 | 0.6470 | 7.4947 | 15.9000 | AID624382; AID624383 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 (µMol) | 3.5805 | 0.0795 | 3.5203 | 9.9390 | AID1053171; AID1053172 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 (µMol) | 3.5805 | 0.0795 | 3.5203 | 9.9390 | AID1053171; AID1053172 |
| Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 2.4198 | 0.4000 | 7.1344 | 54.0000 | AID1417 |
| Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | IC50 (µMol) | 12.5500 | 0.6200 | 16.3255 | 90.4600 | AID2006; AID2018 |
| SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | IC50 (µMol) | 12.5500 | 0.6200 | 16.3255 | 90.4600 | AID2006; AID2018 |
| Myeloid cell leukemia sequence 1 (BCL2-related) | Homo sapiens (human) | IC50 (µMol) | 5.4780 | 0.4415 | 3.7529 | 5.4780 | AID2217 |
| SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | IC50 (µMol) | 12.5500 | 0.6200 | 16.3255 | 90.4600 | AID2006; AID2018 |
| bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 82.7000 | 3.9100 | 83.9944 | 180.9200 | AID1376 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.0000 | 0.0000 | 1.7746 | 10.0000 | AID338305 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cortical actin cytoskeleton | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| microvillus | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| endomembrane system | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| lamellipodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| filopodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| extracellular exosome | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1503177 | Cytotoxicity against human SupT1 cells assessed as decrease in cell viability after 48 hrs by CCK-8 assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID378776 | Cytotoxicity against BC cells at 50 ug/ml by SRB assay | 2006 | Journal of natural products, Sep, Volume: 69, Issue:9 | Cyclopentenones, scaffolds for organic syntheses produced by the endophytic fungus mitosporic dothideomycete sp. LRUB20. |
| AID338306 | Antimicrobial activity against Escherichia coli at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID1503175 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells at 100 uM after 48 hrs by luciferase reporter gene assay relative to control | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID378490 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by microplate alamar blue assay | 2006 | Journal of natural products, Sep, Volume: 69, Issue:9 | Cyclopentenones, scaffolds for organic syntheses produced by the endophytic fungus mitosporic dothideomycete sp. LRUB20. |
| AID1435965 | Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control | |||
| AID1272001 | Inhibition of Saccharomyces cerevisiae alpha-Glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate assessed as formation of para-nitrophenol preincubated for 5 mins followed by addition of substrate measured after 15 mins by microplate read | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Polyketide butenolide, diphenyl ether, and benzophenone derivatives from the fungus Aspergillus flavipes PJ03-11. |
| AID1435967 | Cytotoxicity against human Jurkat cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control | |||
| AID338305 | Displacement of endothelin-1 from ETA receptor in rat A10 cells | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID378492 | Cytotoxicity against human KB cells at 50 ug/ml by SRB assay | 2006 | Journal of natural products, Sep, Volume: 69, Issue:9 | Cyclopentenones, scaffolds for organic syntheses produced by the endophytic fungus mitosporic dothideomycete sp. LRUB20. |
| AID338307 | Antimicrobial activity against Gaeumannomyces graminis var. tritici at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID1435968 | Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control | |||
| AID338309 | Antinematodal activity against Caenorhabditis elegans after 16 to 24 hrs | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| AID664503 | Cytotoxicity against human MCF7 cells at 100 uM after 96 hrs by MTT assay | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic Aspergillus terreus. |
| AID1503176 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID378491 | Cytotoxicity against african green monkey Vero cells at 50 ug/ml by SRB assay | 2006 | Journal of natural products, Sep, Volume: 69, Issue:9 | Cyclopentenones, scaffolds for organic syntheses produced by the endophytic fungus mitosporic dothideomycete sp. LRUB20. |
| AID378775 | Cytotoxicity against human NCI-H187 cells at 50 ug/ml by SRB assay | 2006 | Journal of natural products, Sep, Volume: 69, Issue:9 | Cyclopentenones, scaffolds for organic syntheses produced by the endophytic fungus mitosporic dothideomycete sp. LRUB20. |
| AID1435966 | Cytotoxicity against human HepG2 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control | |||
| AID1435969 | Cytotoxicity against human K562 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control | |||
| AID338308 | Antimicrobial activity against Rhizoctonia solani at <200 ppm | 2002 | Journal of natural products, Jan, Volume: 65, Issue:1 | New chlorinated diphenyl ethers from an Aspergillus species. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.17%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (95.83%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||